Summary
The evaluation cannot determine alignment with the provided FDA-approved prescribing information excerpts; however, multiple safety/clinical management claims (allergy timing, symptom examples, urgency, and pattern-based concern, plus immunologic certainty) are not supported or verifiable from the supplied label text.
Category Scores
Accurate Statements
Cosentyx (secukinumab) is an IL-17A inhibitor.
Supported by 12.1 Mechanism of Action: Secukinumab selectively binds IL-17A and inhibits its interaction with the IL-17 receptor.
Unsupported Statements
Allergic reactions can occur after dosing with Cosentyx.
No provided excerpt explicitly mentions allergic reactions/allergy occurrence as an adverse reaction.
Reported serious allergic reactions to Cosentyx include hypersensitivity reactions such as anaphylaxis.
No provided excerpt includes anaphylaxis or serious allergic reaction details.
Reported serious allergic reactions to Cosentyx include hypersensitivity reactions such as angioedema.
No provided excerpt includes angioedema or serious allergic reaction details.
Patients may experience less severe allergy symptoms (such as rash or hives) after starting Cosentyx treatment.
No provided excerpt includes rash/hives as allergy manifestations or severity progression after starting therapy.
Allergic symptoms indicating a serious reaction should be treated as urgent.
No provided excerpt provides urgency/emergency triage instructions for allergic symptoms.
Severe allergic symptoms after Cosentyx can include trouble breathing and wheezing.
No provided excerpt lists respiratory symptoms as part of hypersensitivity/allergic reactions.
Severe allergic symptoms after Cosentyx can include swelling of the face, lips, tongue, or throat (angioedema).
No provided excerpt includes these angioedema symptom descriptions.
Severe allergic symptoms after Cosentyx can include dizziness or fainting.
No provided excerpt includes these symptom descriptions for hypersensitivity/anaphylaxis.
Severe allergic symptoms after Cosentyx can include widespread hives.
No provided excerpt includes hives as part of hypersensitivity/anaphylaxis.
These severe symptoms can be signs of anaphylaxis or other severe hypersensitivity reactions.
No provided excerpt includes anaphylaxis or hypersensitivity symptom-sign equivalences.
Injection-site reactions (redness, pain, swelling) after biologic injections can occur without being an allergy.
No provided excerpt describes injection-site reactions or distinguishes them from allergy.
Rash after biologic injections can have causes other than allergy, including infections.
No provided excerpt addresses rash etiologies in relation to COSENTYX or distinguishes allergy vs infection.
Allergic reactions after an injection of Cosentyx can occur at any time.
No provided excerpt provides timing guidance for allergic reactions (any time vs early vs delayed).
Clinicians typically focus on symptoms that start soon after Cosentyx dosing and worsen over hours.
No provided excerpt contains clinician timing/assessment guidance for hypersensitivity.
If allergic symptoms develop after subsequent Cosentyx doses as well, that pattern can increase concern for a drug-related allergy.
No provided excerpt includes pattern-based risk assessment for drug-related allergy after subsequent doses.
If a serious allergic reaction occurs with Cosentyx symptoms such as trouble breathing, swelling, or fainting, emergency care should be sought immediately.
No provided excerpt gives emergency-care instructions tied to hypersensitivity symptom examples.
For non-emergency allergy-like symptoms such as hives or a new rash after Cosentyx, patients should contact the prescribing clinician promptly for guidance.
No provided excerpt provides patient triage/contact instructions for allergy-like symptoms (hives/rash).
Risk of allergic reactions to Cosentyx is higher in people with prior drug hypersensitivity reactions (to biologics or other medications).
No provided excerpt includes a risk factor statement about prior hypersensitivity.
A history of anaphylaxis or severe allergic responses should be discussed with the prescriber before continuing Cosentyx therapy.
The provided contraindications excerpt addresses previous serious hypersensitivity reactions, but no provided excerpt contains this counseling/discussion instruction or mentions anaphylaxis specifically.
If a true hypersensitivity reaction is confirmed, the prescriber may consider an alternative treatment within the biologic class or with a different mechanism.
No provided excerpt includes management guidance for confirmed hypersensitivity reactions or mentions switching within class vs different mechanism.
Contradictions
AI Statement
Patients may experience less severe allergy symptoms (such as rash or hives) after starting Cosentyx treatment.
Label Reference
No direct contradiction identified in the provided excerpts.
Important Omissions
Mechanism of action and key on-label contraindication wording is not integrated with the allergy discussion; specifically, the label contraindication is limited to patients with a previous serious hypersensitivity reaction to secukinumab or excipients, but the AI text broadly describes allergy occurrence and management without reflecting this label-specific contraindication basis.
Importance:
Moderate
Boxed warning assessment: the provided label excerpts do not include boxed warnings; the AI response does not indicate whether anaphylaxis/hypersensitivity is present as a boxed requirement (cannot be verified).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
High
Multiple detailed hypersensitivity/allergy symptom and emergency triage instructions are not supported by the provided prescribing-information excerpts, creating risk of misinformation about what reactions to expect and how urgently to act.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Safety/clinical-management claims about allergic reactions (anaphylaxis/angioedema, timing, symptom lists, and emergency triage) are not verifiable from the supplied FDA label excerpts.
Suggested Improvement
Restrict statements to information explicitly present in the provided label excerpts (e.g., IL-17A mechanism; contraindication for previous serious hypersensitivity to secukinumab/excipients). Remove symptom-specific and urgency guidance unless the corresponding label text is supplied and confirms those details.